ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Mar 14, 2022 20:58 JST
Source:
Jacobson Pharma Corporation Limited
Jacobson Pharma's Chairman Uplifts Shareholding to Above 60%
Demonstrates Confidence in Group's Long-term Prospects
HONG KONG, Mar 14, 2022 - (ACN Newswire) - Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma Corporation Limited (the "Company"; together with its subsidiaries, the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, acquired through his controlled entity a total of 20,532,000 shares of the Company (the "Shares") between 15 December 2021 and 14 March 2022 on the market at a total consideration of approximately HK$13,460,000, representing an average price of approximately HK$0.6555 per Share (the "Acquisitions").
The above share purchase represents approximately 1.06% of the total issued share capital of the Company as at 14 March 2022. Following the Acquisitions, Mr. Sum is interested in an aggregate of 1,160,808,000 Shares, representing approximately 60.01% of the total issued share capital of the Company as at the date of the related announcement.
Speaking with sound optimism about the future prospects of the Group, Mr. Sum went on to say, "Albeit the challenging market environment, the overall business, in particular the generic drugs, has shown great strength and resilience in the face of the ongoing pandemic. We remain steadfast to realize the growth potential of our robust product portfolios alongside a strong commercial and operational set-up. I have strong confidence in the long-term development of the Group."
Mr Sum said he might consider further increasing his shareholding in the Company subject to the applicable laws and regulations.
About Jacobson Pharma Corporation Limited (Stock Code: 2633)
Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated engaged in the research, development, production, sale and distribution of essential medicines and specialty drugs. As a major provider of generic drugs in Hong Kong, the Group has one of the most extensive sales and distribution coverage for both the private and public market sectors in Hong Kong, with an expanding reach into strategically selected Asian markets. Carrying a broad product portfolio and taking a pre-eminent market position in a number of therapeutic categories, the Group operates a host of 10 PIC/S GMP licensed production facilities for generic drugs in Hong Kong.
The Group aims at the continued strategic enrichment of its generic drug portfolios through the addition of high value-added products. With its corporate headquarters based in Hong Kong, the Group has also established its operating subsidiaries in China, Macau, Taiwan, Singapore and Cambodia forming a regional commercial platform to tap the market potential in the Asia Pacific and Greater China region. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website:
http://www.jacobsonpharma.com
For media enquiries, please contact:
Strategic Financial Relations Limited
Vicky Lee Tel: (852) 2864 4834 Email:
vicky.lee@sprg.com.hk
Rachel Ko Tel: (852) 2114 2370 Email:
rachel.ko@sprg.com.hk
Mandy Wong Tel: (852) 2114 4900 Email:
mandy.wong@sprg.com.hk
Fax: (852) 2527 1196
Source: Jacobson Pharma Corporation Limited
Sectors: Daily Finance, BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
CleverTap Recognized as a 'Strong Performer' in the Cross-Channel Marketing Hubs, Q4 2024 Report
Nov 22, 2024 22:42 JST
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
Nov 22, 2024 11:00 JST
NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth
Nov 21, 2024 22:59 JST
Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan
Nov 21, 2024 15:35 JST
Deadline to Lead in Securities Fraud Lawsuit Against Humacyte, Inc. (HUMA) is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP
Nov 21, 2024 09:00 JST
ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study
Nov 20, 2024 23:05 JST
Start of Demonstration Test of Two-Phase Direct-to-Chip Cooling in the Air-Cooled Data Center
Nov 20, 2024 15:30 JST
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 11:51 JST
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 20, 2024 10:24 JST
Kingsoft Announces 2024 Third Quarter Results
Nov 19, 2024 18:54 JST
NTT and Olympus Joint Demonstration Shows IOWN APN's Low-latency Capability Can Be Used for Real-time Diagnosis and Treatment on a Remote Server to Realize World's First Cloud Endoscopy System
Nov 19, 2024 15:30 JST
Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings
Nov 19, 2024 09:02 JST
CleverTap Recognized as a Strong Performer in Cross-Channel Marketing Hubs, Q4 2024 Report
Nov 18, 2024 23:30 JST
World's First Successful Trial of Quantum Tokens Created Using Quantum Technology
Nov 18, 2024 17:29 JST
Fujitsu and SAP Fioneer enter partnership to accelerate digital transformation in the insurance industry and deliver services that contribute to customers' sustainable business
Nov 18, 2024 12:31 JST
Expanding Possibilities with the Liquid Hydrogen-Powered GR Corolla in the Season Final Round
Nov 18, 2024 09:25 JST
COP29: Indonesian Special Envoy Hashim Djojohadikusumo Announces EUR 1,2 Billion Green Funding
Nov 16, 2024 18:00 JST
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of LNG-Powered Roll-on/Roll-off Ship TRANS HARMONY EMERALD in Shimonoseki
Nov 15, 2024 18:58 JST
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 17:33 JST
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 15, 2024 14:31 JST
More Latest Release >>
Related Release
Jacobson Pharma Announces FY2025 Interim Results
November 22 2024 10:00 JST
Jacobson Pharma Announces FY2023 Interim Results
November 25 2022 21:21 JST
Jacobson Pharma Announces FY2022 Annual Results
June 29 2022 23:20 JST
Ban Loong, Jacobson & JBM Form Joint Venture to Tap Specialty Drugs and Branded Healthcare Markets in Greater China and Asia
June 15 2022 19:56 JST
Jacobson Pharma Announces FY2022 Interim Results
November 26 2021 19:39 JST
Jacobson Pharma Announces FY2021 Annual Results
June 29 2021 23:19 JST
JBM (Healthcare) Limited Debuts on The Main Board of SEHK
February 05 2021 16:28 JST
JBM (Healthcare) Limited to Be Spun Off from Jacobson Pharma Corporation Limited
January 25 2021 17:20 JST
Jacobson Pharma's Proposed Spin-off and Separate Listing of JBM (Healthcare) Limited on The Main Board of The Stock Exchange of Hong Kong Limited
January 15 2021 23:25 JST
Jacobson Pharma Announces FY2021 Interim Results
November 27 2020 20:10 JST
More Press release >>